Trial · NCT07906652
Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
NCT07906652, Early phase 1, Enrolling by invitation, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia. Trials, record NCT07906652. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906652
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
- NCT number
- NCT07906652
- Status
- Enrolling by invitation
- Phases
- Early phase 1
- Enrollment
- 300 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Moyamoya Disease
- Interventions
- Atorvastatin, Replenishing Five Herbs Decoction, Replenishing Five Herbs Decoction Placebo
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With an Increase of at Least 1 Point in Cerebral Perfusion Staging Score | Baseline (before intervention) and the day after completion of the 3-month treatment course | Cerebral perfusion is staged on 3T moyamoya MRI (non-contrast and contrast-enhanced) perfusion imaging using four parameters (time to peak, TTP; mean transit time, MTT; cerebral blood flow, CBF; cerebral blood volume, CBV), classified into 2 stages and 4 subtypes (II2, II1, I2, I1) and scored 1 to 4 as ordinal data. The percentage of participants whose perfusion staging score increases by at least 1 point after the 3-month intervention compared with baseline is calculated for each group. Images are read by radiologists blinded to group allocation. |
| Secondary | Fugl-Meyer Assessment of Motor Function Score | Baseline and the end of the 3-month intervention | Motor function assessed with the Fugl-Meyer Assessment; scored independently by physicians before the intervention and by a separate group of physicians after the intervention. |
| Secondary | Modified Barthel Index Score | Baseline and the end of the 3-month intervention | Activities of daily living and self-care ability assessed with the Modified Barthel Index (score range 0-100). |
| Secondary | Montreal Cognitive Assessment Score | Baseline and the end of the 3-month intervention | Cognitive function assessed with the Montreal Cognitive Assessment. |
| Secondary | National Institutes of Health Stroke Scale Score | Baseline and the end of the 3-month intervention | Neurological deficit assessed with the NIHSS (score range 0-42). Pre-specified clinical efficacy categories are defined by the percentage change in score: excellent, a decrease of 50% or more; good, a decrease of 30% or more; fair, a decrease of 20% or more; poor, not meeting these criteria. |
| Secondary | Incidence of New Intracerebral Hemorrhage | From randomization to the end of the 3-year telephone follow-up | Events identified by telephone follow-up every two weeks and confirmed by medical records and imaging. |
| Secondary | Incidence of Recurrent or New Cerebral Infarction | From randomization to the end of the 3-year telephone follow-up | Events identified by telephone follow-up every two weeks and confirmed by medical records and imaging. |
| Secondary | All-Cause Mortality | From randomization to the end of the 3-year telephone follow-up | Events identified by telephone follow-up every two weeks and confirmed by medical records and imaging. |
| Other | Incidence of Adverse Events and Serious Adverse Events | From first dose to the end of the study (including the 3-year telephone follow-up) | Assessed at each visit and by telephone follow-up every two weeks; recorded in the safety follow-up log with time of onset, severity, management, relationship to the study drug, and outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906652
GET https://conductscience.org/api/trials/v1/NCT07906652/registered